Genelux Brings in Arrowhead Pharmaceuticals Exec as New Finance Chief

Dow Jones

2025/02/03

By Denny Jacob

Genelux named Matthew Pulisic as chief financial officer.

The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share.

Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company.

Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

February 03, 2025 06:58 ET (11:58 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2508112609"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508112609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508112609?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-03 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508112609","market":"other","top_or_hot":-1,"title":"Genelux Brings in Arrowhead Pharmaceuticals Exec as New Finance Chief","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Genelux named Matthew Pulisic as chief financial officer. \n</p>\n<p>\n  The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share. \n</p>\n<p>\n  Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company. \n</p>\n<p>\n  Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2025 06:58 ET (11:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genelux Brings in Arrowhead Pharmaceuticals Exec as New Finance Chief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenelux Brings in Arrowhead Pharmaceuticals Exec as New Finance Chief\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-03 19:58</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Genelux named Matthew Pulisic as chief financial officer. \n</p>\n<p>\n  The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share. \n</p>\n<p>\n  Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company. \n</p>\n<p>\n  Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2025 06:58 ET (11:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508112609","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508112609","pubTimestamp":1738583880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Genelux named Matthew Pulisic as chief financial officer.The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share.Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company.Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","ARWR":"Arrowhead Research Corporation","BK4139":"生物科技","GNLX":"Genelux Corporation"},"translate_title":"Genelux聘请Arrowhead Pharmaceuticals高管担任新任财务主管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1,"GNLX":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Genelux named Matthew Pulisic as chief financial officer. \n\n\n  The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share. \n\n\n  Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company. \n\n\n  Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2025 06:58 ET (11:58 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}